The next generation of human papillomavirus vaccines: Nonavalent vaccine V503 on the horizon

Chatterjee A. Expert Rev Vaccines. 2014;13:1279-90

Human papillomavirus (HPV) infection with 'high-risk' genotypes is associated with ano-genital and oropharyngeal cancers. Two currently licensed prophylactic HPV vaccines designed to prevent disease associated with HPV 16 and 18 are in use around the world. Both vaccines have very high efficacy for prevention of vaccine type-associated cervical precancers, preventing approximately 70% of these lesions. Quadrivalent HPV vaccine has also been shown to prevent HPV16/18-associated vaginal, vulvar and anal precancers, and HPV6/11-associated ano-genital warts. To broaden protection against HPV genotypes not in the current vaccines, 'second-generation' vaccines with additional genotypes are under development. Merck, Sharp and Dohmehas submitted a Biologics License Application for its investigational nonavalent HPV vaccine V503 to the US Food and Drug Administration, with standard review being granted. The nonavalent HPV vaccine appears to be safe and effective in preventing persistent infection and precancerous lesions associated with HPV types 16/18/31/33/45/52/58, as well as genital warts related to HPV types 6 and 11.

Food and drug administration approves Gardasil 9 for prevention of certain cancers caused by five additional types of human papillomavirus

FDA News Release, December 10, 2014

Gardasil 9 is a vaccine approved for use in females ages 9 through 26 and males ages 9 through 15. It is approved for the prevention of cervical, vulvar, vaginal and anal cancers caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV types 6 or 11. Gardasil 9 adds protection against five additional HPV types - 31, 33, 45, 52 and 58 which cause approximately 20% of cervical cancers and are not covered by previously Food and Drug Administration (FDA)-approved HPV vaccines. Randomized, controlled clinical study was conducted in the US and internationally in approximately 14,000 females ages 16 through 26 who tested negative for vaccine HPV types at the start of the study. Study participants received either Gardasil or Gardasil 9. Gardasil 9 was determined to be 97% effective in preventing cervical, vulvar and vaginal cancers caused by the five additional HPV types (31, 33, 45, 52, and 58). In addition, Gardasil 9 is as effective as Gardasil for the prevention of diseases caused by the four shared HPV types (6, 11, 16, and 18) based on similar antibody responses in participants in clinical studies. Due to the low incidence of anal cancer caused by the five additional HPV types, the prevention of anal cancer is based on Gardasil\'s demonstrated effectiveness of 78% and additional data on antibodies in males and females who received Gardasil 9. Gardasil 9 is administered as three separate shots, with the initial dose followed by additional shots given 2 and 6 months later. For all of the indications for use approved by the FDA, Gardasil 9\'s full potential for benefit is obtained by those who are vaccinated prior to becoming infected with the HPV strains covered by the vaccine. The safety of Gardasil 9 was evaluated in approximately 13,000 males and females. The most commonly reported adverse reactions were injection site pain, swelling, redness, and headaches.

Virus-like particles for the prevention of human papillomavirus associated malignancies

Wang J, Richard B.S. Roden. Expert Rev Vaccines 2013;12

As compared to peptide/protein-based vaccines, naked DNA vectors and even traditional attenuated or in active virus vaccines, virus-like particles (VLPs) are an attractive vaccine platform because they offer a combination of safety, ease of production, and both high-density B-cell epitope display and intracellular presentation of T-cell epitopes that induce potent humoral and cellular immune responses respectively. Human papillomavirus (HPV) vaccines based on VLP production by recombinant expression of major capsid antigen L1 in yeast (Gardasil^®^ Merck and Co.) or insect cells (Cervarix^®^, GlaxoSmithKline) have been licensed for the prevention of cervical and ano-genital infection and disease associated with the genotypes targeted by each vaccine. Current HPV L1-VLP vaccines provide type-restricted protection, requiring highly multivalent formulations to broaden coverage to the dozen or more oncogenic HPV genotypes. This raises the complexity and cost of vaccine production. Given the previous success with L1 VLP-based vaccines against HPV, VLPs have been also adopted as platforms for many second generation HPV and non-HPV vaccine candidates with both prophylactic and therapeutic intent. The use of therapeutic vaccination against cervical cancer is attractive since it introduces possibility of a noninvasive approach to directly target HPV infected cells via the induction of CD8 cytotoxic T-lymphocyte responses, thereby reducing the potential for side effects. Chimeric HPV VLPs (cVLPs) in which the T-cell epitopes of HPV E6, E7 or both are fused to the C-terminus of either HPV L1-VLP or L1/L2-VLPsact like a "delivery vehicle" carrying the extra epitopes of the non-structural HPV proteins into the target cell for entry into the class I presentation pathway. However, to date, cVLP have not generated therapeutic responses in patients, suggesting consideration of targeting cellular immunity to the lesion site (e.g. route and site of immunization) and approaches to modulate the lesion microenvironment are warranted.

Human papillomavirus vaccine acceptability among men: A systematic review and meta-analysis

Newman PA, Logie CH, Doukas N, AsakuraK. Sex Transm Infect 2013;89: 568-74

**Background**: The prevalence of anal human papillomavirus (HPV) infection is estimated at around 15% in heterosexual men, 60% in men who have sex with men (MSM) who are HIV negative, and 95% in HIV positive MSM. Worldwide, the majority of anal and penile cancers among men are associated with HPV infections. The quadrivalent HPV vaccine (HPV4; Gardasil) was licensed in the USA for men in 2009. In 2011, the US Advisory Committee on Immunization Practices approved and recommended routine use of HPV4 for boys aged 11-21 years, with approval for administration up to age 26 years, in order to prevent genital warts and anal cancer.

**Objective**: To understand rates of HPV vaccine acceptability and factors correlated with HPV vaccine acceptability among men.

**Review Methods**: Calculation of mean HPV vaccine acceptability across studies. Meta-analysis using a random effects model on studies reporting correlates of HPV vaccine acceptability was conducted. All studies were assessed for risk of bias.

**Results**: Of 301 identified studies, 29 were included. Across 22 studies (*n* = 8360), weighted mean HPV vaccine acceptability = 50.4 (SD 21.5) (100-point scale). Among 16 studies (*n* = 5048) included in meta-analyses, perceived HPV vaccine benefits, anticipatory regret, partner thinks one should get vaccine and healthcare provider recommendation had medium effect sizes, and the following factors had small effect sizes on HPV vaccine acceptability: Perceived HPV vaccine effectiveness, need for multiple shots, fear of needles, fear of side effects, supportive/accepting social environment, perceived risk/susceptibility to HPV, perceived HPV severity, number of lifetime sexual partners, having a current sex partner, non-receipt of hepatitis B vaccine, smoking cigarettes, history of sexually transmitted infection, HPV awareness, HPV knowledge, cost, logistical barriers, being employed and non-white ethnicity.

**Conclusion**: Public health campaigns that promote positive HPV vaccine attitudes and awareness about HPV risk in men, and interventions to promote healthcare provider recommendation of HPV vaccination for boys and mitigate obstacles due to cost and logistical barriers may support HPV vaccine acceptability for men. Future investigations employing rigorous designs, including intervention studies, are needed to support effective HPV vaccine promotion among men.

Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against ano-genital pre-cancer in women with evidence of prior human papillomavirus exposure

Sex Transm Infect 2013; 89: A265-A266 doi: 10.1136/sextrans-2013-051184.0825

**Background**: It is unclear whether L1-VLP-based human papillomavirus (HPV) vaccines are efficacious in preventing ano-genital pre-cancer in women with prior vaccine-type HPV exposure. Participants in the phase III efficacy trials were not excluded if infected at baseline (HPV-DNA and serology were performed in retrospect); the efficacy in this sub-group of vaccines can be derived from published reports.

**Methods**: A systematic review and meta-analysis were conducted to compare the efficacy of L1-VLP-based HPV vaccines with control (hepatitis A or placebo). Randomized controlled trials (including post-RCT follow-on cohort studies) were identified from Medline, Embase, Web of Science^SM^, PubMed, Cochrane (and quoted references). Three vaccines were evaluated: Cervarix™ containing HPV-16/18 VLPs (GSK), Gardasil^®^ containing HPV-6/11/16/18 VLPs (Merck), and an HPV-16 monovalent vaccine (Merck Research Laboratories).

**Results**: Three RCT reports and one post-RCT follow-on study met the eligibility criteria, comprising data from 13,339 women who were included in the vaccine studies but had evidence of HPV infection at baseline. Efficacy data were synthesized using a Der Simonian and Laird weighted random-effect model. The mean odds ratio (OR) and 95% confidence interval (CI) for the association between Cervarix™, Gardasil^®^ and HPV-16 monovalent vaccine and HPV-associated cervical intraepithelial neoplasia grade 3 or worse (CIN3+) was 0.90 (CI: 0.56, 1.44) and for the association between Gardasil^®^ and HPV-associated vulval/vaginal intraepithelial neoplasia grades 2-3 (VIN2-3/VaIN2-3) OR 1·20 (CI: 0·07, 20·40).

**Conclusion**: There was no evidence that the HPV vaccines are effective in preventing vaccine-type HPV-associated precancer in women with evidence of prior HPV exposure in this analysis. However, these studies were not designed to investigate the efficacy in this group, so statistical power (sample size, follow-up period and event rate) was insufficient to detect a small effect size. Longer follow-up is also needed to detect possible prevention of re-infection.

Potential benefits of second-generation human papillomavirus vaccines

Kiatpongsan S, Campos NG, KimJJ. PLoS ONE (2012) 7 (11): E48426

**Background**: Current prophylactic vaccines against human papillomavirus (HPV) target two oncogenic types (16 and 18) that contribute to 70% of cervical cancer cases worldwide. Second-generation prophylactic HPV vaccines, currently in clinical trials, may hold several advantages over the current vaccines, including protection against additional oncogenic HPV types, less dependence on cold chain storage and distribution, and more efficient delivery mechanisms (e.g., oral and mucosal routes instead of the parenteral route), facilitating integration with other childhood vaccines in routine immunization programs.

**Objective**: To quantify the range of additional benefits conferred by second-generation HPV prophylactic vaccines that are expected to expand protection to five additional oncogenic types (31, 33, 45, 52 and 58).

**Methods**: A microsimulation model of HPV and cervical cancer calibrated to epidemiological data from two countries (Kenya and Uganda) was used to estimate reductions in lifetime risk of cervical cancer from the second-generation HPV vaccines. The independent and joint impact of uncertain factors (i.e. distribution of HPV types, co-infection with multiple HPV types, and unidentifiable HPV types in cancer) were explored and vaccine properties (i.e., cross-protection against nontargeted HPV types), compared against currently-available vaccines.

**Results**: Assuming complete uptake of the second-generation vaccine, an absolute increase in cervical cancer reduction of 26.1% in Kenya and 17.9% in Uganda, compared with complete uptake of current vaccines. The range of added benefits was 19.6% to 29.1% in Kenya and 14.0% to 19.5% in Uganda, depending on assumptions of cancers attributable to multiple HPV infections and unidentifiable HPV types. These effects were blunted in both countries when assuming vaccine cross-protection with both the current and second-generation vaccines.

**Conclusion**: Second-generation HPV vaccines that protect against additional oncogenic HPV types have the potential to improve cervical cancer prevention. Co-infection with multiple HPV infections and unidentifiable HPV types can influence vaccine effectiveness, but the magnitude of effect may be moderated by vaccine cross-protective effects. These benefits must be weighed against the cost of the vaccines in future analyses.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: A model-based analysis

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer E, Coutlée F, Laprise JF, Malagó T, Brissonet M. J Natl Cancer Inst 2012;104:1712-3

**Background**: Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now licensed in several countries. Furthermore, clinical trials examining the efficacy of a nonavalent vaccine are underway. We aimed to compare the potential population-level effectiveness of the bivalent, quadrivalent, and candidate nonavalent HPV vaccines.

**Methods**: We developed an individual-based, transmission-dynamic model of HPV infection and disease in a population stratified by age, gender, sexual activity, and screening behavior. The model was calibrated to highly stratified sexual behavior, HPV epidemiology, and cervical screening data from Canada.

**Results**: Under base case assumptions, vaccinating 12-year-old girls (70% coverage) with the bivalent (quadrivalent) vaccine is predicted to reduce the cumulative incidence of ano-genital warts (AGWs) by 0.0% (72.1%), diagnosed cervical intraepithelial neoplasia lesions 2 and 3 (CIN2 and-3) by 51.0% (46.1%), and cervical squamous cell carcinoma (SCC) by 31.9% (30.5%), over 70 years. Changing from a bivalent (quadrivalent) to a nonavalent vaccine is predicted to reduce the cumulative number of AGW episodes by an additional 66.7% (0.0%); CIN2 and-3 episodes by an additional 9.3% (12.5%); and SCC cases by an additional 4.8% (6.6%) over 70 years. Differences in predicted population-level effectiveness between the vaccines were most sensitive to duration of protection and the time horizon of analysis. The vaccines produced similar effectiveness at preventing noncervical HPV-related cancers.

**Conclusion**: The bivalent vaccine is expected to be slightly more effective at preventing CIN2 and-3 and SCC in the longer term, whereas the quadrivalent vaccine is expected to substantially reduce AGW cases shortly after the start of vaccination programs. Switching to a nonavalent vaccine has the potential to further reduce precancerous lesions and cervical cancer.
